Bangalore (Karnataka) [India], March 30 (ANI): Strides Pharma Science Ltd announced Monday that it received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration last month at the company’s flagship facility.
The inspection was linked to specific extended release requests made from the site. Receipt of the EIR confirms the successful completion of inspections, the company said in a statement.
The flagship Bangalore plant has the capacity to produce finished dosage formulations in multiple dosage formats including tablets, capsules, ointments, creams and liquids.
It is also capable of manufacturing complex sustained-release tablet formulations, which is one of the areas of focus of the company.
Strides has a large portfolio of extended releases for the United States and other regulated markets with the ability to manufacture these products at multiple locations.
Strides is a global pharmaceutical company that operates primarily in regulated markets. It has an “In Africa, for Africa” strategy as well as an institutional enterprise to serve donor funded markets.
The company’s global manufacturing sites are located in Bengaluru (two sites), Pondicherry, Chennai, Singapore, Milan, Nairobi and Florida. It focuses on “hard to make” products that are sold in over 100 countries. (ANI)